Use of tranexamic acid (TXA) reduced the risk of major bleeding in patients undergoing urologic surgery, results from the randomized POISE-3 trial showed. Among more than 1,100 patients, 6.1% of those ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...

Methods: This prospective three-arm trial enrolled men with treatment-naïve, localized PCa pursuing pelvic radiotherapy (RT) alone or with concomitant ≥ 6 months ADT. Patients receiving ADT were ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

Darolutamide is an androgen receptor inhibitor (ARI) with low blood-brain barrier penetration, potentially resulting in low reactive testosterone increases and less feminizing adverse events (AEs). In ...

Surgery and radiotherapy are the main treatments for localized prostate cancer. Although many retrospective studies have compared their efficacy, evidence from the Middle East and North Africa (MENA) ...

Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial). This is an ASCO Meeting Abstract from the ...